Newest Breast Cancer Biomarkers Will Predict Therapy Outcomes
This article was originally published in The Gray Sheet
Executive Summary
The next generation of breast cancer biomarkers will be able to better predict therapy outcomes, aid in patient selection and monitor therapy effectiveness, said Walter Carney, head of Oncogene Science for Siemens Medical Solutions Diagnostics
You may also be interested in...
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.